306325-13-3

Basic information

• Product Name: 6-BROMO-5-METHYLISATIN
• Synonyms: AG-690/08980048;ARONIS016716;BIM-0014096.P001;CBMicro_014209;STK042825;ZINC02052963;6-BROMO-5-METHYLISATIN;6-bromo-5-methyl-indoline-2,3-dione
• CAS NO: 306325-13-3
• Molecular Formula: C₉H₆BrNO₂
• Molecular Weight: 240.05
• Product Categories: Indane/Indanone and Derivatives
• Mol File: 306325-13-3.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Density: 1.714±0.06 g/cm3(Predicted)
• PKA: 8.84±0.20(Predicted)
• CAS DataBase Reference: 6-BROMO-5-METHYLISATIN(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-5-METHYLISATIN(306325-13-3)
• EPA Substance Registry System: 6-BROMO-5-METHYLISATIN(306325-13-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 306325-13-3(Hazardous Substances Data)

Usage

General Description

6-Bromo-5-methylisatin is a chemical compound with the formula C9H7BrNO2. It is an isatin derivative with a bromine atom and a methyl group attached to the aromatic ring. 6-BROMO-5-METHYLISATIN is known for its fluorescent properties and is used in organic synthesis and as a fluorescent label in biological studies. It has also been studied for its potential pharmacological activities, including as an anti-inflammatory and anti-cancer agent. Additionally, 6-Bromo-5-methylisatin has been investigated for its potential use in the development of new materials for various applications.

Upstream product

• 7745-91-7 3-bromo-4-methylaniline 
• 147149-83-5 N-(3-bromo-4-methyl-phenyl)-2-hydroxyimino-acetamide 

Downstream Products

• 356524-80-6 C₁₉H₁₈BrN₃O₅ 

Relevant articles and documents

Utilizing Solubility differences to achieve regiocontrol in the synthesis of substituted quinoline-4-carboxylic acids

A practical method for the regiocontrolled synthesis of substituted quinoline-4-carboxylic acids is described. Solubility differences between the product quinoline regioisomers enable their facile separation, thus avoiding any challenging chromatographic purifications and allowing access to highly substituted quinoline compounds in three steps from commercially available anilines.

Structural Basis for the Synthesis of Indirubins as Potent and Selective Inhibitors of Glycogen Synthase Kinase-3 and Cyclin-Dependent Kinases

Pharmacological inhibitors of glycogen synthase kinase-3 (GSK-3) and cyclin-dependent kinases have a promising potential for applications against several neurodegenerative diseases such as Alzheimer's disease. Indirubins, a family of bis-indoles isolated from various natural sources, are potent inhibitors of several kinases, including GSK-3. Using the cocrystal structures of various indirubins with GSK-3β, CDK2 and CDK5/p25, we have modeled the binding of indirubins within the ATP-binding pocket of these kinases. This modeling approach provided some insight into the molecular basis of indirubins' action and selectivity and allowed us to forecast some improvements of this family of bis-indoles as kinase inhibitors. Predicted molecules, including 6-substituted and 5,6-disubstituted indirubins, were synthesized and evaluated as CDK and GSK-3 inhibitors. Control, kinase-inactive indirubins were obtained by introduction of a methyl substitution on N1.